Kezar Life Sciences, Inc. (KZR)
Automate Your Wheel Strategy on KZR
With Tiblio's Option Bot, you can configure your own wheel strategy including KZR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 30, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Kezar Life Sciences, Inc. (NASDAQ: KZR ) related to its sale to Aurinia Pharmaceuticals Inc. Under the terms of the proposed transaction, Kezar shareholders are expected to receive $6.955 per share in cash and one non-transferable contingent value …
Read More
Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE, March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Aurinia. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results. “.
Read More
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Published: March 24, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA tri.
Read More
About Kezar Life Sciences, Inc. (KZR)
- IPO Date 2018-06-21
- Website https://www.kezarlifesciences.com
- Industry Biotechnology
- CEO Christopher J. Kirk
- Employees 55